Prospects for personalised treatment of patients with radioiodine-avid locally recurrent or metastatic thyroid cancer
AffiliationBristol Cancer Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol,
MetadataShow full item record
AbstractAlthough most patients with metastatic or inoperable locally recurrent differentiated thyroid cancer have radioiodine-avid disease, the outcome for patients who do not achieve remission with radioiodine therapy is poor. Most centres use fixed empirical activities of radioiodine to treat these patients, which is in contrast to other areas of oncology, where there is a shift to more individualised treatment. The use of dosimetry techniques to calculate a more appropriate activity of radioiodine for each patient may increase the effectiveness of radioiodine therapy but is more complex, time-consuming and of unproven benefit. This review addresses some of the limitations of empirical radioiodine therapy, discusses existing dosimetry-based approaches to individualising therapy and proposes further work in this area. A prospective randomised controlled trial comparing empirical activities of radioiodine with activities guided by a combination of lesional dosimetry and maximum safe dose has not been carried out previously. Although considerable challenges in the design of such a study remain, a network of centres in the UK now has the potential to take this forward.
CitationBeasley M, Garcez K. Prospects for Personalised Treatment of Patients with Radioiodine-avid Locally Recurrent or Metastatic Thyroid Cancer. Clin Oncol (R Coll Radiol). 2021;33(2):75-9.
- Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?
- Authors: Sun F, Gerrard GE, Roberts JK, Telford T, Namini S, Waller M, Flux G, Gill VM
- Issue date: 2017 May
- Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
- Authors: Brown SR, Hall A, Buckley HL, Flanagan L, Gonzalez de Castro D, Farnell K, Moss L, Gregory R, Newbold K, Du Y, Flux G, Wadsley J
- Issue date: 2019 Jun 14
- Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
- Authors: Abuqbeitah M, Demir M, Kabasakal L, Çavdar İ, Uslu-Beşli L, Yeyin N, Razavikhosroshahi S, Sönmezoğlu K
- Issue date: 2018 Nov
- Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
- Authors: de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ, de Klerk JM
- Issue date: 2004 Sep
- 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
- Authors: Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, Bockisch A
- Issue date: 2007